Evidence map›Paper›PMID 38015975›Full record

ArticlePloS one2023

Racial, ethnic, and age disparities in the association of mental health symptoms and polysubstance use among persons in HIV care.

Thibaut Davy-Mendez, Varada Sarovar, Tory Levine-Hall, Alexandra N Lea, Amy S Leibowitz, Mitchell N Luu, Jason A Flamm, C Bradley Hare, Jaime Dumoit Smith, Esti Iturralde and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Thibaut Davy-MendezDepartment of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, CA, United States of America.ORCID 0000-0002-8505-9268
Varada SarovarDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States of America.
Tory Levine-HallDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States of America.
Alexandra N LeaDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States of America.ORCID 0000-0001-6194-699X
Amy S LeibowitzDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States of America.
Mitchell N LuuOakland Medical Center, Kaiser Permanente Northern California, Oakland, CA, United States of America.
Jason A FlammSacramento Medical Center, Kaiser Permanente Northern California, Sacramento, CA, United States of America.
C Bradley HareSan Francisco Medical Center, Kaiser Permanente Northern California, San Francisco, CA, United States of America.
Jaime Dumoit SmithDepartment of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, CA, United States of America.
Esti IturraldeDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States of America.
James DilleyDepartment of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, CA, United States of America.
Michael J SilverbergDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States of America.
Derek D SatreDepartment of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, CA, United States of America.
Kaiser Permanente · USUniversity of California, San Francisco · USKaiser Permanente Oakland Medical Center · USKaiser Permanente Sacramento Medical Center · USKaiser Permanente San Francisco Medical Center · US

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Substance Use Disorders Treatment/Services Research Training ProgramT32DA007250 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Derek D Satre, Janice Y Tsoh · 1991 to 2026
$7.4M
Implementing computerized substance use and depression screening and evidence-based treatments in an HIV primary care populationR01DA043139 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SATRE, DEREK D, SILVERBERG, MICHAEL J · 2016 to 2020
$3.2M
Mentoring alcohol use intervention research in HIV health care settingsK24AA025703 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Derek D Satre · 2018 to 2026
$1.8M
Addressing Barriers to the Comprehensive Use of Statins in HIV: The ABACUS-HIV StudyK01HL169020 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Thibaut Davy-Mendez · 2023 to 2026
$600k
NHLBI NIH HHS K01 HL169020NIAAA NIH HHS K24 AA025703NIAID NIH HHS P30 AI050410NIDA NIH HHS R01 DA043139NIDA NIH HHS T32 DA007250
6 · The paper itself

Abstract

We characterized polysubstance use burden and associations with mental health problems across demographic subgroups of PWH. In 2018-2020, as part of a primary care-based intervention study, PWH in care at three medical centers in Kaiser Permanente Northern California were screened for depression (PHQ-9≥10), anxiety (GAD-2≥3), and substance use (Tobacco, Alcohol, Prescription medication, and other Substance use [TAPS]≥1 per substance). We used Poisson regression to estimate prevalence ratios (PRs) comparing polysubstance use prevalence (TAPS≥1 for ≥2 substances) between PWH with positive screens for depression or anxiety vs. neither, among all PWH, and stratified by race/ethnicity and age (restricted to men), adjusting for sociodemographics, CD4, and HIV load. Screened PWH (N = 2865) included 92% men, 56% White, 19% Black, and 15% Hispanic PWH, with a median age of 55 years. Overall, polysubstance use prevalence was 26.4% (95% CI 24.9%-28.1%). PWH with depression or anxiety (n = 515) had an adjusted polysubstance use PR of 1.26 (1.09-1.46) vs. PWH with neither (n = 2350). Adjusted PRs were 1.47 (1.11-1.96), 1.07 (0.74-1.54), and 1.10 (0.85-1.41) among Black, Hispanic, and White men, respectively. Adjusted PRs did not differ by age group. Interventions should consider jointly addressing mental health and substance use problems and potential drivers, e.g. stigma or socioeconomic factors.

Indexed as

HIV InfectionsSubstance-Related DisordersAnxietyEthnicityFemaleHumansMaleMental HealthMiddle Aged

Identifiers

PMID38015975
PMCPMC10684077
OpenAlexW4389077141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.